Literature DB >> 31173554

Exemestane Plus Ovarian Function Suppression Is the Best Adjuvant Treatment of Premenopausal Women With Endocrine-Responsive Breast Cancer at Higher Risk of Relapse and With HER2-Negative Tumors.

Fabio Conforti1, Laura Pala1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31173554      PMCID： PMC6881096          DOI： 10.1200/JCO.19.00559

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  3 in total

1.  Ovarian Suppression in Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.

Authors:  Kathy Pan; Linda Diana Bosserman; Rowan T Chlebowski
Journal:  J Clin Oncol       Date:  2019-02-11       Impact factor: 44.544

2.  Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials.

Authors:  Meredith M Regan; Olivia Pagani; Gini F Fleming; Barbara A Walley; Karen N Price; Manuela Rabaglio; Rudolf Maibach; Barbara Ruepp; Alan S Coates; Aron Goldhirsch; Marco Colleoni; Richard D Gelber; Prudence A Francis
Journal:  Breast       Date:  2013-10-02       Impact factor: 4.380

3.  Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.

Authors:  Prudence A Francis; Olivia Pagani; Gini F Fleming; Barbara A Walley; Marco Colleoni; István Láng; Henry L Gómez; Carlo Tondini; Eva Ciruelos; Harold J Burstein; Hervé R Bonnefoi; Meritxell Bellet; Silvana Martino; Charles E Geyer; Matthew P Goetz; Vered Stearns; Graziella Pinotti; Fabio Puglisi; Simon Spazzapan; Miguel A Climent; Lorenzo Pavesi; Thomas Ruhstaller; Nancy E Davidson; Robert Coleman; Marc Debled; Stefan Buchholz; James N Ingle; Eric P Winer; Rudolf Maibach; Manuela Rabaglio-Poretti; Barbara Ruepp; Angelo Di Leo; Alan S Coates; Richard D Gelber; Aron Goldhirsch; Meredith M Regan
Journal:  N Engl J Med       Date:  2018-06-04       Impact factor: 91.245
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.